<DOC>
	<DOCNO>NCT00568958</DOCNO>
	<brief_summary>In study , 140 heavy drinking young adult ( age 18-25 ) provide brief counseling either naltrexone , medication FDA-approved treatment alcohol dependence , placebo course 8 week . A novel strategy use administer low-dose naltrexone , daily dose combine targeted dose anticipation high-risk situation . The main hypothesis daily + target naltrexone result great reduction frequency heavy drinking compare daily + target placebo .</brief_summary>
	<brief_title>Naltrexone Heavy Drinking Young Adults</brief_title>
	<detailed_description>NIAAA designate underage drinking priority research area . Of note , high prevalence problem alcohol use among young adult age 18-25 . Heavy drinking occur period important immediate lifelong adverse consequence . Behavioral intervention , notably BASICS ( Brief Alcohol Screening Intervention College Students ) , develop help young adult reduce drink . Although intervention effective , include college student mandate treatment others minimal motivation stop drinking , effect size modest , suggest new approach need enhance intervention . A promising strategy yet test young adult use opiate antagonist naltrexone . In research , naltrexone show reduce amount alcohol consume , even absence strong internal motivation change , reduce frequency heavy drinking problem drinker seek treatment . Thus propose conduct 8 week double-blind placebo-controlled trial test combine efficacy BASICS + naltrexone 132 young adult age 18-25 drink heavily . A novel strategy use administer low-dose naltrexone , daily dose combine targeted dose anticipation high-risk situation . The main hypothesis daily + target naltrexone result great reduction frequency heavy drinking compare daily + target placebo . In order enhance sensitivity able ass naltrexone 's effect drinking , daily rating obtain treatment . These permit u examine alternative measure alcohol involvement ( e.g. , report subjective intoxication , estimate blood alcohol level ) addition traditional measure base number drink consume . These data also use examine potential mediator ( e.g. , crave , subjective effect alcohol ) treatment response order well understand effect naltrexone . The durability treatment effect examine 3 , 6 12 month randomization . Demonstration efficacy naltrexone population provide essential information need adoption college counsel center health care setting commit reduce risk heavy drinking young adult .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Alcohol Drinking</mesh_term>
	<mesh_term>Alcoholic Intoxication</mesh_term>
	<mesh_term>Alcohol-Induced Disorders</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Each subject must : 1 . Be age 18 25 ; 2 . Report heavy drink 4 time past 4 week . Heavy drinking define 4 drink woman 5 drink men occasion ; 3 . Be able read English show evidence significant cognitive impairment . 4 . That woman childbearing potential ( i.e. , hysterectomy , bilateral oophorectomy , tubal ligation ) , nonlactating , practice reliable method birth control , negative urine pregnancy test prior initiation treatment . No subject may : 1 . Exhibit current , clinically significant physical disease abnormality basis medical history , physical examination , routine laboratory evaluation , include AST ALT level great 3 time normal bilirubin level great 110 % normal . Individuals common medical condition ( e.g. , asthma , diabetes mellitus , thyroid disease ) adequately control relationship primarycare practitioner exclude ; 2 . Exhibit serious psychiatric illness ( i.e. , schizophrenia , bipolar disorder , severe major depression , panic disorder , borderline personality disorder , organic mood mental disorder , substantial suicide violence risk ) history psychological examination ; 3 . Have current diagnosis DSMIV drug dependence nicotine , lifetime history DSMIV opiate dependence ; 4 . Have current DSMIV diagnosis alcohol dependence clinically severe define ) history seizure , delirium , hallucination alcohol withdrawal , b ) Clinical Institute Withdrawal Assessment scale ( Sullivan et al. , 1989 ) score &gt; 8 , c ) report drink avoid withdrawal symptom , ) prior treatment withdrawal . 5 . Have use opioids concomitant therapy psychotropic drug past month , except subject stable dose Selective Serotonin Reuptake Inhibitor least two month indication Major Depressive Disorder , Premenstrual Syndrome ( PMS ) , Premenstrual Dysphoric Disorder ( PMDD ) exclude ; SSRIs allow due safety profile relative class antidepressant . 6 . Have history hypersensitivity naltrexone ; 7 . Be consider investigator unsuitable candidate receipt investigational drug . 8 . The investigator may exclude participant complete daily questionnaire less half day intake treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>heavy episodic drinking</keyword>
	<keyword>young adult</keyword>
	<keyword>naltrexone</keyword>
	<keyword>BASICS counseling</keyword>
	<keyword>alcohol-related consequence</keyword>
	<keyword>double-blind trial</keyword>
	<keyword>randomize clinical trial</keyword>
</DOC>